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Abstract Article Info 
Introduction: Nasopharyngeal cancer (NPC) is the most common head and neck malignancy with an ever-
increasing incidence. Inflammatory biomarkers has been proven to be an indicator of immune response against 
malignancies. A more advanced clinical stage will elicit a worse immune response against tumor cells. A simple 
and low cost laboratory examination using biomarkers such as lymphocyte monocyte ratio is needed in order to 
determine the prognosis of NPC patients based on immune response against malignancies. 
Objective: To determine the association between lymphocyte monocyte ratio and the clinical stage of patients 
with NPC. 
Methods: A case control study was used on data obtained from medical records of NPC patients who had 
undergone staging in the Otolaryngology Outpatient Department of Sardjito Public Hospital from 2015 to 2018. 
Results: Total of 64 patients were enrolled in the study, comprising of 38 males (59.4%) and 26 females (40.6%). 
There were 33 (51.6%) patients aged ≤ 50 years and 31 patients (48.4%) aged > 50 years, with early and 
advanced clinical stages of 32 patients in each age group. The most common histopathological type is 
undifferentiated carcinoma (WHO Type 3) (60 patients, 93.7%) followed by non-keratinizing carcinoma (WHO 
Type 2) (4 patients, 6.3%). The cutoff ratio for lymphocyte monocyte ratio was obtained from ROC Curve 
analysis, which was 2,64. Statistical analysis using chi-square test showed an association between LMR and 
clinical staging of NPC patients with a P value < 0,001, with an Odds Ratio of 6.53 (CI 95%; 2.19 – 19.42). 
Thus, patients with a lower LMR was shown to have 6.53 times the risk of having a more advanced clinical 
stage compared to higher LMR. 
Conclusion: There was found to be an association between lymphocyte monocyte ratio and clinical staging of 
nasopharyngeal cancer patients. 
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Nasopharyngeal cancer (NPC) is a form of squamous cell carcinoma 
originating from the epithelial lining of the nasopharynx. The tumor arises 
from the Rosenmuller fossa, a transitional zone of columnar epithelial tissue 
to squamous epithelial tissue [1]. Several risk factors in the development of 
NPC include hereditary interactions, human leukocyte antigen (HLA), 
Ebstein-Barr virus (EBV), consumption of preserved fish, and chronic 
respiratory tract diseases.  
In Indonesia, NPC is the fourth most common malignancy, with an 
incidence of 6.2 in 100.000 annually, and is the most common head and neck 
malignancy [2, 3]. In Central Java, undifferentiated NPC (WHO Type 3) is 
the most common malignancy. In Yogyakarta, NPC is the number one 
malignancy found in men and places third amongst women [4]. The 
incidence of NPC in men is two to three times more than in women, with 
peak incidence at age 50-60 years, with risks of relapse and lower survival 
rates higher in older patients [5]. 
Several current studies have shown the role of systemic inflammatory 
responses in increasing the chance of metastatic disease and tumor 
progression by way of apoptosis inhibition, angiogenesis promotion, and 
DNA damage [6]. Inflammatory biomarkers have shown to indicate 
interactions between tumor microenvironment and host immunity, one of 
which is the ratio of lymphocyte monocyte (LMR). Lymphocytes are an 
important component of the adaptive immune sytem, and lymphocyte 
infiltration indicates an effective anti-tumor cellular immune response. A 
high pretreatment lymphocyte count has been shown to be a good 
independent prognostic factor in patients with head and neck malignancies 
[7]. Lymphocyte, specifically T-cells, plays an important role in the process 
of tumor cell destruction and controlling neoplastic progressivity. 
Monocytes are one of components of inflammatory cell infiltrates found in 
various malignancies. Monocytes in peripheral circulation and in tumor 
microenvironments (macrophages) produce pro angiogenesis factors such 
as vascular endothelial growth factor (VEGF) which contributes to promote 
tumor growth [8]. 
Prompt diagnosis and treatment of NPC correlates with an increase of 
survival. Molecular biomarkers, like plasma EBV DNA, are often linked 
with the prognosis of NPC patients [9]. However, high costs and 
inavailability of resources often hinder the utilization of such techniques. 
Thus, it is important to source out other factors to predict the prognosis of 
NPC patients, particularly relatively cheap and feasible indicators. A 
complete blood count including lymphocyte and monocyte counts, is simple 
and easy to perform. It is a routine examination, performed especially in the 
pretreatment stage of NPC patients. Evaluations are necessary to determine 
any associations between LMR and NPC clinical staging in Dr. Sardjito 
Public Hospital. This study aimed to determine the association between 
lymphocyte monocyte ration and clinical staging of nasopharyngeal cancer 
patients. 
2. MATERIALS AND METHODS 
This is an analytical observational study to determine any association 
between lymphocyte monocyte ratio and clinical staging of nasopharyngeal 
cancer patients. It is a case control study, with a one-time analysis of the 
study subjects after pretreatment staging. 
The target population of this study are NPC patients. The accessible 
population are NPC patients treated in the Otolaryngology Outpatient 
Department of Dr. Sardjito General Hospital. This study samples NPC 
patients at the Otolaryngology Outpatient Department of Dr. Sardjito 
General from January 2015 to December 2018 which fulfils the inclusion 
and exclusion criteria. The inclusion criteria are NPC patients with medical 
records documenting the disease in detail and accurate (including 
nasopharyngeal biopsy, CT Scan, chest x ray, abdominal ultrasound, and 







bone survey) and has laboratory results of lymphocyte and monocyte from 
peripheral blood samples obtained less than two weeks prior to staging. 
Exclusion criteria include signs and symptoms of active infection and 
concurrent hematological disorders with a Karnofsky scale ≤ 70%. 
3. RESULTS 
3.1 Association between LMR and NPC Clinical Staging 
The LMR cutoff point based on receiver operating characteristic curve 
analysis was found to be 2.64 with a sensitivity of 0.719 and specificity of 
0.719. LMR was divided into two categories: low (≤ 2.64) and high (> 2.64). 
Table 1. Subject Characteristics  
Variable Total (n=64) Percentage (%) Mean (± SD) 
Sex 
Male 38 59.4 - 
Female 26 40.6 - 
Age  50.84(±10,21) 
≤50 yo 33 51.6  
>50 yo 31 48.4  
Histopathology 
WHO type 1 0 0  
WHO type 2 4 6.3  
WHO type 3 60 93.7  
Lymphocyte   1.54(±0,58) 
Monocyte   0.62(±0,29) 
LMR 2.87(±1,36) 
>2,64 32 50  
≤2,64 32 50  
 
Picture 1. Cut off point of LMR based on ROC curve 
 
Table 2. Association between LMR and NPC clinical staging 
LMR 
Stage 
OR 95%CI P 
Advanced (%) Early (%) 
 
Low (≤ 2.64) 23 (35.93) 9 (14.07) 6.531 2.196- 19.421 <0.001 
High (> 2.64) 9 (14.07) 23 (35.93)    
Total (%) 32 (50) 32 (50)    
From the table above, it can be seen that 9 patients with high LMR was 
found to have advanced disease (case) (14.07%), whilst 23 patients were in 
the early stages of disease (control) (35.93%). In the low LMR category, 
there were 23 patients with advanced diseases (35.93%) and 9 patients in 





3.2. Analysis of Cinical Staging Amongst Subject Characteristics 
Table 3. Analysis of Clinical Staging in Sex Groups 





Sex    
Male 20 (31.25) 18 (28.12) 0.611 
Female 12 (18.75) 14 (21.88)  
Total 32 (50) 32 (50)  
The study subjects were categorized into each sex group, and from total of 
64 samples, 38 were male and 26 were female. Chi-square test analysis did 
not show a statistically significant difference between the two groups with 
a p-value of 0.611. 
Table 4. Analysis of Clinical Staging in Age Groups 




     P 
Age    
≤ 50 yo 13 (20,31) 20 (31,25) 0,080 
> 50 yo 19 (29,69) 12 (18,75)  
Total (%) 32 (50) 32(50)  
In this study, the oldest patient was 73 years old, and the youngest is 26 
years old, with a mean of 50.84±10.21 years. The largest age group in this 
study is 41-50 years (37.5%) followed by 51-60 years (31.25%). This study 
categorizes the age groups into two cohorts: 50 years and below and older 
than 50 years. Chi-square test analysis did not show a statistically significant 
difference between the case and control groups with a p-value of 0.080. 
Table 5. Analysis of Clinical Staging in Histopathological Type Groups 
The World Health Organization classifies NPC into three histopathological 
types: type 1 (typical keratinizing squamous cell) none found is this study, 
type 2 (nonkeratinizing carcinoma) 4 subjects in this study, and type 3 
(undifferentiated carcinoma) 60 subjects in this study. Statistical analysis 
did not reveal any statistically significant difference in the case and control 
groups regarding histopathological type (p-value 0.613) 
3.3. Analysis of LMR Amongst Subject Characteristics 




Low (≤ 2.64) (%) High (> 2.64) (%) 
 Age   
 ≤50 yo 18 (28.12)  15 (23.44) 0.453 
>50  yo 14 (21.88) 17 (26.56)  
  Sex    
Male 20 (31.25) 18 (28.12) 0.611 
Female 12 (18.75) 14 (21.88)  
 
WHO    
Type 1 0(0) 0(0) 1.000 
Type 2 2 (3.12) 2 (3.12)  
Type 3 30 (46.88) 30 (46.88)  
We analyze LMR in association with subject characteristic. From this 
study we found that there were no significant difference amongst LMR with 
age (P value of 0.453), sex (P value of 0.611), and WHO histopathology (P 
value of 1.000). 
4. DISCUSSION 
BFrom the research results it was found that the OR value was 6.53. it 
means that Patients who have a low LMR at NPC are 6.53 times more likely 
to get it at an advanced clinical stage than patients who have a high LMR 
ratio at NPC. In other hand, the OR value of 6.53 means that the probability 
of patients who have a low LMR at NPC to occur at an advanced clinical 
stage is 86.71%.  
The results of this study are in accordance with those conducted by Zhu 
et al. [10] which stated that low LMR tends to provide clinical 
manifestations in the form of increased stage, chemotherapy resistance, and 
Subject Characteristic 
Advanced Stage 
 n (%) 
Early Stage 
n (%) P 
Histopathology   0,613 
WHO type 1 0(0) 0(0)  
WHO type 2 1 (1.56) 3 (4.69)  
WHO type 3 31 (48.44) 29 (45.31)  
Total (%) 32 (50) 32 (50)  







residual tumors> 1 cm after debulking. Low LMR values are associated with 
lower OS and PFS in ovarian epithelial cancer patients. 
In a meta-analysis study by Teng et al. [11], similar results were 
obtained. The systematic review compared pre-therapy LMR scores on 
overall survival (OS) and distant metastase free survival (DFS) in 18 solid 
tumor studies that included gastrointestinal cancer, urinary tract cancer, lung 
cancer and nasopharyngeal cancer. From this study, it was found that there 
was a significant relationship between the high pre-therapy LMR on the high 
OS and DFS in solid tumor patients. Based on these results it can be 
concluded that LMR has a prognostic value, especially for OS and DFS. Lee 
et al. [12], Zhang et al. [13], Liu et al. [14], Tham et al. [7] reinforce this 
prognostic value that the higher the LMR will give increased OS cancer 
patients. Jiang et al. [15] and Lin et al. [9] examined the relationship 
between LMR and OS in metastatic NPC patients. In line with other studies, 
the results show that LMR is an independent prognostic factor for OS that 
has been chemotherapy. 
Based on this research, it can be seen that the levels of lymphocytes and 
monocytes in the peripheral circulation have a relationship with the 
manifestations of NPC patients as measured by the clinical stage. This study 
wanted to determine the relationship between LMR levels and the patient's 
clinical stage. Peripheral circulation homeostasis, in this case lymphocytes 
and monocytes play an important role in describing the balance of pro-tumor 
and anti-tumor activities. Lymphocytes with anti-tumor activity against 
monocytes in the tissue (macrophages) are more predominantly pro-tumor. 
Iwahori et al. [16] in his research stated that activity in microenvironment 
of tumors is closely related to peripheral blood circulation. Using bis-
specific T-cell engager (BiTE) technology, it was found that the cytotoxicity 
of TIL was correlated with peripheral blood T cells so it could be concluded 
that antigen-specific T cell activity in microenvironmental tumors could be 
detected in peripheral blood circulation. 
The study subjects were categorized into each sex group, and from total 
of 64 samples, 38 were male and 26 were female. According to Fachiroh et 
al. [4], this malignancy tends to be more common in males than females 
with a ratio of 2:1. Research by Xie et al. [17] also shows the same results, 
with a male to female ratio of 2-3:1. The incidence of NPC in males is higher 
than in females can be based on risk factors that are more dominant in males. 
These risk factors include smoking habits and occupational dust exposure. 
Meanwhile, the role of the hormone estrogen in inhibiting the growth of 
NPC has also begun to be widely studied. This gender role was stated in two 
hypotheses. The first hypothesis stated that the lower incidence of NPC in 
males was due to habits and behavior, especially in diagnostic delays. The 
second hypothesis stated that there was a protective effect of estrogen which 
affects the progression of NPC. This was based on the increasing data in the 
incidence of post-menopausal NPC and the low progression of pre-
menopausal NPC [17, 18]. 
In this study, the oldest patient was 73 years old, and the youngest was 
26 years old, with a mean of 50,84± 10,21 years. The largest age group in 
this study is 41-50 years followed by 51-60 years. The results support the 
study by Jiang et al. [15], which stated that there was no significant 
difference between the LMR value and gender (P = 0.342) in NPC patients. 
However, again research by Meng et al. [19] stated that there were different 
things in healthy populations. This study illustrated that women have a 
significantly higher LMR than men (P <0.001). 
The World Health Organization classified NPC into three 
histopathological types, and Statistical analysis did not reveal any 
statistically significant difference in the case and control groups regarding 
histopathological type (p-value 0,613). In a study by Huang et al. [20] found 
that there was a significant difference between increasing TAM and 
increasing the clinical stage of NPC. The increase in EBV titer had a positive 
correlation with the increase in TAM in NPC patients. From the results of 
the cytokine profile analysis, it was found that NPC cells with EBV 
replication were active in recruiting monocytes via VEGF, and it was 
converted into TAM by M-CSF via the NF-kB pathway. In this study, it was 
also found that there was a negative correlation between TAM and T cells 
in tissue samples of NPC patients which indicated that macrophage 
infiltration in tumor tissue might be related to NPC immunosuppression.  
5. CONCLUSION 
There was found to be an association between lymphocyte monocyte 
ratio to clinical staging in nasopharyngeal cancer patients (p-value < 0,001).  
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